Relay Therapeutics, Inc. (RLAY)

Market Cap	619.77M
Revenue (ttm)	7.68M
Net Income (ttm)	-333.39M
Shares Out	171.44M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	227,532
Open	3.670
Previous Close	3.730
Day's Range	3.605 - 3.700
52-Week Range	1.775 - 10.720
Beta	1.63
Analysts	Strong Buy
Price Target	18.40 (+408.99%)
Earnings Date	Aug 5, 2025

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 261
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2024, Relay Therapeutics's revenue was $10.01 million, a decrease of -60.83% compared to the previous year's $25.55 million. Losses were -$337.71 million, -1.25% less than in 2023.

Analyst Summary

According to 11 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $18.4, which is an increase of 408.99% from the latest price.

Price Target

$18.4

(408.99% upside)

Analyst Consensus: Strong Buy